全文获取类型
收费全文 | 21261篇 |
免费 | 1016篇 |
国内免费 | 378篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 379篇 |
妇产科学 | 122篇 |
基础医学 | 2187篇 |
口腔科学 | 179篇 |
临床医学 | 1795篇 |
内科学 | 6661篇 |
皮肤病学 | 173篇 |
神经病学 | 617篇 |
特种医学 | 261篇 |
外科学 | 1311篇 |
综合类 | 3452篇 |
预防医学 | 1492篇 |
眼科学 | 127篇 |
药学 | 2641篇 |
14篇 | |
中国医学 | 820篇 |
肿瘤学 | 340篇 |
出版年
2023年 | 304篇 |
2022年 | 630篇 |
2021年 | 883篇 |
2020年 | 745篇 |
2019年 | 694篇 |
2018年 | 797篇 |
2017年 | 651篇 |
2016年 | 612篇 |
2015年 | 672篇 |
2014年 | 1631篇 |
2013年 | 1643篇 |
2012年 | 1345篇 |
2011年 | 1439篇 |
2010年 | 1037篇 |
2009年 | 1067篇 |
2008年 | 1027篇 |
2007年 | 817篇 |
2006年 | 795篇 |
2005年 | 747篇 |
2004年 | 605篇 |
2003年 | 500篇 |
2002年 | 367篇 |
2001年 | 389篇 |
2000年 | 282篇 |
1999年 | 267篇 |
1998年 | 118篇 |
1997年 | 85篇 |
1996年 | 92篇 |
1995年 | 190篇 |
1994年 | 170篇 |
1993年 | 248篇 |
1992年 | 231篇 |
1991年 | 191篇 |
1990年 | 162篇 |
1989年 | 165篇 |
1988年 | 147篇 |
1987年 | 103篇 |
1986年 | 109篇 |
1985年 | 108篇 |
1984年 | 123篇 |
1983年 | 38篇 |
1982年 | 100篇 |
1981年 | 43篇 |
1980年 | 53篇 |
1979年 | 43篇 |
1978年 | 26篇 |
1977年 | 25篇 |
1976年 | 32篇 |
1973年 | 22篇 |
1972年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的考察半夏泻心汤联合甘精胰岛素注射液对脾弱胃强型2型糖尿病患者血糖及免疫指标的影响。方法选取2019年1月~2020年12月于天津市河西区康复医院诊治的脾弱胃强型2型糖尿病患者120例,随机分为对照组和观察组,每组60例,对照组仅给予甘精胰岛素注射液,观察组给予半夏泻心汤联合甘精胰岛素注射液。比较两组治疗后1个月和3个月患者临床治疗有效率,治疗前、治疗后1个月和3个月糖化血红蛋白(glycosylated hemoglobin,HbA1c)和空腹血糖(fasting plasma glucose,FPG)及免疫细胞CD3+、CD4+、CD8+和CD4+/CD8+水平。结果相比于对照组,观察组治疗后1个月和3个月临床治疗有效率显著提高(P<0.05);两组治疗前血糖和免疫相关指标相比,差异无统计学意义(P>0.05),治疗后1个月和3个月,两组患者HbA1c、FPG和CD8+相比于治疗前均显著降低,而CD3+、CD4+和CD4+/CD8+显著升高(P<0.05);治疗后3个月,两组患者HbA1c、FPG和CD8+相比于治疗后1个月均显著降低,而CD3+、CD4+和CD4+/CD8+显著升高(P<0.05);观察组治疗后1个月和3个月HbA1c、FPG和CD8+相比于对照组均显著降低,而CD3+、CD4+和CD4+/CD8+显著升高(P<0.05)。结论半夏泻心汤联合甘精胰岛素注射液治疗脾弱胃强型2型糖尿病患者的临床效果较好,能够有效降低患者血糖水平,改善机体免疫水平。 相似文献
2.
3.
A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics
《Drug discovery today》2022,27(3):808-821
Tyrosine kinases are enzymes that can transfer a phosphate group from ATP to a specific protein tyrosine, serine or threonine residue within a cell, operating as a switch that can turn ‘on’ and ‘off’ causing different physiological alterations in the body. Mutated kinases have been shown to display an equilibrium shift toward the activated state. Types I–III have been studied intensively leading to drugs like imatinib (type II), cobimetinib (type III), among others. It is the same scenario for types V–VII; however, there is a lacuna in information regarding type IV inhibitors, although recently some advances have surfaced. This review aims to accumulate the knowledge gained so far about type IV inhibitors. 相似文献
4.
目的: 探讨chemerin在合并2型糖尿病口腔鳞癌(T2DM-OSCC)患者肿瘤组织中的表达及临床意义,分析其与临床病理参数及预后的关系,为T2DM-OSCC患者的治疗提供理论依据。方法: 收集2009年1月—2014年12月在青岛大学附属医院口腔颌面外科收治的T2DM-OSCC患者(87例)和普通OSCC患者(113例),利用免疫组织化学(IHC)方法检测2组肿瘤及癌旁组织中chemerin的表达,采用SPSS 26.0软件包对数据进行统计学分析。结果: T2DM-OSCC患者肿瘤组织中chemerin的表达显著高于癌旁组织(P<0.05),其高表达与颈淋巴结转移、TNM分期、肿瘤分化程度和肿瘤复发相关(P<0.05)。T2DM-OSCC患者肿瘤组织中chemerin表达显著高于普通OSCC患者(P<0.05)。合并2型糖尿病chemerin高表达组术后5年总生存率显著低于其他组(P<0.05),肿瘤组织中chemerin表达是影响T2DM-OSCC患者5年总生存率的独立预后因素。结论: Chemerin在T2DM-OSCC中的表达较普通OSCC高,其高表达提示T2DM-OSCC患者的预后更差。Chemerin有望成为T2DM-OSCC患者判断预后的潜在指标和治疗靶点。 相似文献
5.
《Annales de cardiologie et d'angeiologie》2022,71(1):41-52
Heart failure (HF) has high event rates, mortality, and is challenging to manage in clinical practice. Clinical management is complicated by complex therapeutic strategies in a population with a high prevalence of comorbidity and general frailty. In the last four years, an abundance of research has become available to support multidisciplinary management of heart failure from within the hospital through to discharge and primary care as well as supporting diagnosis and comorbidity management. Within the hospital setting, recent evidence supports sacubitril-valsartan combination in frail, deteriorating or de novo patients with LVEF ≤ 40%. Furthermore, new strategies such as SGLT2 inhibitors and vericiguat provide further benefit for patients with decompensating HF. Studies with tafamidis report major clinical benefits specifically for patients with ATTR cardiac amyloidosis, a remaining underdiagnosed and undertreated disease. New evidence for medical interventions supports his bundle pacing to reduce QRS width and improve haemodynamics as well as ICD defibrillation for non-ischemic cardiomyopathy. The Mitraclip reduces hospitalisations and mortality in patients with symptomatic, secondary mitral regurgitation and ablation reduces mortality and hospitalisations in patients with paroxysmal and persistent atrial fibrillation. In end-stage HF, the 2018 French Heart Allocation policy should improve access to heart transplants for stable, ambulatory patients and, mechanical circulatory support should be considered to avoid deteriorating on the waiting list. In the community, new evidence supports that improving discharge education, treatment and patient support improves outcomes. The authors believe that this review fills the gap between the guidelines and clinical practice and provides practical recommendations to improve HF management. 相似文献
6.
7.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(1):151-159
Background & aimsTo determine the trends of self-reported non-adherence rates among adults taking Type 2 medicines (T2D) medicines between 2017 and 2019 and to identify the patterns for the frequently reported reasons for non-adherence in the United States.Methods & resultsData from the National Health and Wellness Survey, a self-administered, internet-based cross-sectional survey of US adults from 2017 to 2019 was used. Non-adherence was measured using the self-reported Medication Adherence Reasons Scale (MAR-Scale). Frequencies were used to identify the reasons for non-adherence for insulin and non-insulin therapies for T2D.Data were obtained from 2983 respondents in 2017, 5416 in 2018, and 5268 in 2019. Based on the MAR-Scale, the self-reported medication non-adherence rate was 25% in 2017, 21% in 2018, and 27% in 2019. The most common reason for non-adherence across all the three years was simple forgetfulness, yet patients reported the lowest mean number of days missing medication for that reason. Though less frequently reported, non-adherence lasted longer when patient did not know how to take their medicines, cost was a reason, or had concerns about the long term effects of the medicines.ConclusionsWith no significant improvement in adherence with T2D medicines over time, regardless of better awareness and extensive diabetes education, focus should be on individualized non-adherence reasons-based interventions. 相似文献
8.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(7):1742-1752
Background and aimTo evaluate the effectiveness of structured exercise appropriate the circadian rhythm in terms of blood sample test (BST), functionality and quality of life (QoL) in individuals with type 2 diabetes.Methods and resultsThis was a parallel-group, single-blind, crossover study. Thirty individuals with type 2 diabetes aged 35–65 years were enrolled in the study and allocated into 2 groups as the Morning Chronotype (MC) Group (n = 15) and the Evening Chronotype (EC) Group (n = 15) using Morningness-Eveningness Questionnaire which was used to determine the chronotypes. Participants were evaluated in terms of BST, functionality and QoL at the beginning of the study (T0), at 6 (T1), 12 (T2), and 18 (T3) weeks after the study started. A structured exercise program for 3 days a week over 6 weeks was applied in accordance with the chronotypes (T1-T2) and cross-controlled for the chronotypes (T2-T3). Significant differences were found in favor of the exercise given at the appropriate time for the chronotype in all parameters in both groups within groups (T0-T1-T2-T3) (p < 0.05). In the time1group interactions, exercise in accordance with the appropriate chronotype in both groups provided the highest statistical improvement in all parameters (p < 0.05).ConclusionIt was concluded that structured exercise performed at the appropriate time for chronotype improves HbA1c, fasting blood glucose, HDL-LDL cholesterol, triglyceride, total cholesterol, functionality and quality of life in type 2 diabetes. This variation in blood values was observed to reflect the quantitative effects of exercise administered according to the circadian rhythm in individuals with type 2 diabetes.Trial registrationClinicalTrials.gov (NCT04427488). The protocol of the study was registered at ClinicalTrials.gov (NCT04427488). 相似文献
9.
目的:对2型糖尿病患者进行回顾性研究,探讨中医证型分布和相关因素之间的联系。方法:将湖南省卫生健康委信息统计中心的三甲中医院病历数据进行筛选、清理,最终选取898例患者作为研究对象,并进行回顾性分析,研究患者中医证型并分析证型与年龄、性别、实验室指标之间的关系。结果:898例2型糖尿病患者中证型最多的为肝肾阴虚,合并疾病较多的是心脑血管疾病;在年龄与性别方面,不同中医证型患者分布,差异有统计学意义(P<0.05);实验室指标方面,糖化血红蛋白(HbA1c)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TAG)、血肌酐(Cr)、血尿素氮(BUN)、谷草转氨酶(GOT)、平均血小板体积(MPV)、纤维蛋白原(FIB)不同证型间分布差异均有统计学意义(均P<0.05),其余指标不同证型间比较差异无统计学意义(P>0.05)。结论:性别、年龄、实验室指标可以在一定程度上反映出2型糖尿病不同中医证型的区别,对于2型糖尿病的治疗应及时检测以上指标的水平值,并明确相应的证型,针对性地给予辨证论治或中西医结合治疗,在疾病的中后期要预防心脑血管疾病以及各种并发症的发生,改善患者的生命质量。 相似文献
10.
《Clinical breast cancer》2022,22(6):560-566
BackgroundIn the United States, Europe, and Asia, a consensus has been reached that there is a higher risk of breast cancer in high density breasts. However, there are some contrary reports that suggest the absence of an association between breast composition and breast cancer subtype; thus, there is conflicting evidence. The purpose of this study was to investigate trends in the incidence of breast cancer subtypes according to breast composition and analyze the survival rates in Japanese women.Patients and MethodsBetween 2007 and 2008, 1258 Japanese patients with invasive breast cancer who underwent mammography and obtained a pathological diagnosis in our institution were included in the study. We compared cancer subtypes with breast composition types (dense and non-dense breast), and classified them based on initial mammography findings. Information on 5- and 10-year survival rates was collected by chart review for patients with dense and nondense breasts. Statistical analysis was performed using the Pearson's chi-square test for breast composition and cancer subtype. The effect of breast composition on mortality was examined using a multivariate Cox proportional hazards model, and adjusted hazard ratios were calculated.ResultsNo significant difference was found between breast cancer subtype and breast composition (P = .08). Five-year (log-rank test, P = .09) and 10-year (log-rank test, P = .31) survival rates were not significantly different between breast composition types.ConclusionThere was no significant association between breast composition and cancer subtypes. There was also no significant difference in the prognosis between patients with and without dense breasts. 相似文献